| __timestamp | Bristol-Myers Squibb Company | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 72049000 |
| Thursday, January 1, 2015 | 3909000000 | 110777000 |
| Friday, January 1, 2016 | 4946000000 | 156328000 |
| Sunday, January 1, 2017 | 6066000000 | 175820000 |
| Monday, January 1, 2018 | 6547000000 | 143944000 |
| Tuesday, January 1, 2019 | 8078000000 | 160152000 |
| Wednesday, January 1, 2020 | 11773000000 | 188519000 |
| Friday, January 1, 2021 | 9940000000 | 258234000 |
| Saturday, January 1, 2022 | 10137000000 | 311103000 |
| Sunday, January 1, 2023 | 10693000000 | 384447000 |
| Monday, January 1, 2024 | 11949000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for Bristol-Myers Squibb Company and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Bristol-Myers Squibb demonstrated a significant increase in cost efficiency, with their cost of revenue growing by approximately 172%, from $3.9 billion in 2014 to $10.7 billion in 2023. In contrast, HUTCHMED's cost of revenue rose by about 434%, from $72 million to $384 million, reflecting their expanding operations.
While Bristol-Myers Squibb's larger scale is evident, HUTCHMED's rapid growth highlights its emerging presence in the industry. This comparison underscores the diverse strategies employed by pharmaceutical giants and emerging players alike, offering insights into their operational efficiencies and market dynamics.
Pfizer Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Bristol-Myers Squibb Company vs HUTCHMED (China) Limited: Examining Key Revenue Metrics
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Trends: Pharming Group N.V. vs HUTCHMED (China) Limited
Cost of Revenue Trends: ACADIA Pharmaceuticals Inc. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Travere Therapeutics, Inc.